Bailard’s Five Prime Therapeutics FPRX Stock Holding History
Bought
Maintained
Sold
Bailard's FPRX Position: Q2 2021 in Review
Bailard sold out of Five Prime Therapeutics (FPRX) in Q2 2021, closing a stake of 22,000 shares — an estimated $829K sold.
Bailard first reported a position in FPRX in Q1 2019 and held it in 4 quarters. The position peaked at $829K in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Bailard reported no remaining Five Prime Therapeutics position as of Q2 2021 after selling out during the quarter.
- Bailard sold 22,000 Five Prime Therapeutics shares in Q2 2021, an estimated $829K.
- Bailard first reported a position in Five Prime Therapeutics in Q1 2019 and held it in 4 quarters.
- Bailard's Five Prime Therapeutics position peaked at $829K in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics as of Q2 2021.
Based on Bailard's 13F filing for Q2 2021, filed 13 Aug 2021.